Table 3.

Impact of covariates on antiretroviral therapy adherence: multivariate modelling.

	Model coefficient (95% CI; P value)
	Univariate model	Multivariate model
Canadaa
Age	0.0045 (0.0019 to 0.0070; <0.001)	0.0056 (0.0031 to 0.0082; <0.001)
Sex, male vs. female	0.11 (0.044 to 0.18; 0.001)	0.053 (−0.014 to 0.12; 0.1)
ART regimen (index date), MTR vs. STR	−0.39 (−0.45 to −0.33; <0.001)	−0.39 (−0.46 to −0.33; <0.001)
Western Canadab
Age	0.011 (0.0072 to 0.014; <0.001)	0.0091 (0.0055 to 0.013; <0.001)
Sex, male vs. female	0.23 (0.15 to 0.31; <0.001)	0.16 (0.075 to 0.24; <0.001)
ART regimen (index date), MTR vs. STR	−0.33 (−0.41 to −0.26; <0.001)	−0.34 (−0.42 to −0.26; <0.001)
Chronic disease score	0.014 (−0.0067 to 0.035; 0.2)	−0.041 (−0.075 to −0.0071; 0.02)
Pill burden, high vs. low	0.048 (0.021 to 0.075; <0.001)	0.081 (0.038 to 0.13; <0.001)

ART, antiretroviral therapy; CI, confidence interval; MTR; multitablet regimen; STR, single-tablet regimen.

^aExcluding British Columbia, Nova Scotia, Quebec, Prince Edward Island, Yukon, Nunavut, and the Northwest Territories.

^bManitoba, Saskatchewan, Alberta.